Physician profile
Stephen R Hazelrigg
NPI 1205817996
$3,904.55
in general payments reported to CMS, 2019-2025
8 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $213 · 2021: $792 · 2022: $244 · 2023: $752 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,225 · Food and Beverage: $893 · Education: $37.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,224.86 |
| Food and Beverage | $892.99 |
| Education | $37.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,865.49 | 2019-2025 | Aveir |
| Atricure, INC. | $679.33 | 2020-2023 | |
| Abiomed | $663.05 | 2021-2023 | Impella |
| Edwards Lifesciences Corporation | $466.88 | 2020-2023 | Mitris Resilia Mitral Valve |
| Medtronic, INC. | $137.30 | 2023-2025 | Corevalve Evolut R, Cardioblate |
| Depuy Synthes Sales INC. | $92.50 | 2023 | Matrixrib |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hazelrigg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.